Dulaglutide (Trulicity)
Eli Lilly's once-weekly GLP-1 receptor agonist — notable for its pre-filled, single-dose auto-injector that doesn't require needle attachment. Strong tolerability profile and cardiovascular outcome data. Less potent than semaglutide for weight loss, but a useful option for T2D patients with tolerability concerns.
What Is Dulaglutide?
Dulaglutide (brand name: Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly. Unlike liraglutide (daily) and semaglutide (weekly, requires needle attachment), Trulicity uses a proprietary single-use auto-injector where the needle is fully hidden and auto-retracts — making it notably easier to use for patients who are needle-phobic or new to injectable medications.
Dulaglutide is approved in India for type 2 diabetes management. It activates GLP-1 receptors through the same mechanism as semaglutide and liraglutide but is structurally distinct — it is a GLP-1 analogue fused to an immunoglobulin Fc fragment (IgG4-Fc), which extends its half-life to approximately 5 days, enabling weekly dosing.
Mechanism of Action
Dulaglutide activates GLP-1 receptors with the same downstream effects as other GLP-1 agonists:
- Glucose-dependent insulin secretion — insulin released only when blood glucose is elevated (no hypoglycemia risk)
- Glucagon suppression — reduced hepatic glucose output
- Slowed gastric emptying — extended postprandial satiety
- Appetite suppression via hypothalamic GLP-1 receptors
The REWIND trial (PubMed, 2019) provides the key cardiovascular outcome data for dulaglutide.
REWIND Trial — Cardiovascular Evidence
The REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial enrolled 9,901 adults with T2D over 5.4 years. Key findings:
- 12% reduction in MACE (cardiovascular death, non-fatal MI, non-fatal stroke) versus placebo
- The trial notably included patients with lower cardiovascular risk than previous GLP-1 trials — 69% had established CVD vs 90%+ in SUSTAIN-6 and LEADER trials — making the results more broadly applicable
- Cardiovascular benefit appeared consistent across subgroups including patients without prior CVD
This makes dulaglutide potentially valuable for primary cardiovascular prevention in T2D patients — a broader population than previous trial designs.
Weight Loss Profile
Dulaglutide produces modest weight loss compared to semaglutide and tirzepatide:
| Dose | Average Weight Loss | HbA1c Reduction |
|---|---|---|
| 0.75mg/week | 1.5–2kg | 0.7–1.0% |
| 1.5mg/week | 2–3kg | 1.0–1.4% |
| 3mg/week | 3–4kg | 1.4–1.7% |
| 4.5mg/week | 4–5kg | 1.6–1.8% |
At maximum dose (4.5mg), dulaglutide approaches the weight loss seen with Ozempic 1mg but remains below Wegovy (2.4mg semaglutide). For patients whose primary goal is significant weight loss, semaglutide or tirzepatide will be more effective.
Tolerability Advantage
Dulaglutide is generally considered one of the better-tolerated GLP-1 agonists, particularly at starting doses. Head-to-head studies comparing dulaglutide with semaglutide show:
- Lower rates of nausea and vomiting at equivalent starting doses
- The auto-injector design eliminates needle anxiety — the needle is never visible
- Injection site reactions are rare
This tolerability advantage makes dulaglutide a useful first injectable GLP-1 for patients who are hesitant about injections or have had bad experiences with GI side effects from other medications.
Trulicity's single-use auto-injector pen is unique: the needle is completely hidden, automatically inserted, and retracts after injection. No separate needle attachment or dialing required. This makes it among the easiest GLP-1 injections for first-time users in India.
Who Benefits Most from Dulaglutide?
- T2D patients who are needle-phobic or hesitant about self-injection
- Patients who have experienced significant GI side effects with semaglutide and want a potentially better-tolerated alternative
- T2D patients seeking proven cardiovascular risk reduction with established REWIND data
- Elderly T2D patients where ease of use is a priority
- Patients who need weekly injection but prefer not to manage needles separately
Comparison: Dulaglutide vs Other GLP-1 Agonists
| Drug | Frequency | Avg Weight Loss | CV Trial | Injector |
|---|---|---|---|---|
| Dulaglutide (Trulicity) | Weekly | 2–5kg | REWIND (12% MACE) | Auto-injector, no needle handling |
| Semaglutide (Ozempic) | Weekly | 5–12% | SUSTAIN-6 (26% MACE) | Multi-dose pen, attach needle |
| Tirzepatide (Mounjaro) | Weekly | 21–22% | SURPASS-CVOT (ongoing) | Auto-injector pen |
| Liraglutide (Victoza) | Daily | 3–4kg | LEADER (13% MACE) | Multi-dose pen, attach needle |
Biomarker Monitoring on Dulaglutide
- HbA1c: Every 3 months initially; expect 1.0–1.4% reduction at 1.5mg
- Fasting glucose and fasting insulin
- Lipid panel: Modest triglyceride and LDL improvement
- Weight and waist circumference: Monthly
- Renal function (eGFR): Annually — GLP-1 agonists generally protective for kidneys
Frequently Asked Questions
Is Trulicity available in India?
Yes. Trulicity (dulaglutide) is available in India from Eli Lilly and is approved by CDSCO for type 2 diabetes. It is available at major hospital pharmacies and pharmacy chains in metro cities. It requires a prescription as a Schedule H drug.
How does dulaglutide compare to Ozempic?
Semaglutide (Ozempic) is generally more potent — producing greater HbA1c reduction and significantly more weight loss. Dulaglutide's advantages are tolerability (typically fewer GI side effects at starting doses) and its unique auto-injector that eliminates needle handling. For patients who tolerate both, semaglutide typically provides better metabolic outcomes.
What is the dose of dulaglutide?
Start at 0.75mg once weekly for 4 weeks, then increase to 1.5mg/week for maintenance. For additional response, doses of 3mg and 4.5mg are available. Maximum dose is 4.5mg/week. Most patients are maintained at 1.5mg unless additional efficacy is needed.
Does dulaglutide cause weight loss?
Yes, modestly. At 1.5mg/week, expect 2–3kg average weight loss. At maximum 4.5mg dose, 4–5kg is typical. This is much less than semaglutide or tirzepatide. Dulaglutide is not primarily a weight loss drug, but T2D patients typically see clinically meaningful modest reductions.